Kairos Pharma’s (KAPA) “Buy” Rating Reaffirmed at D. Boral Capital

Kairos Pharma (NYSEAMERICAN:KAPA)‘s stock had its “buy” rating reiterated by equities researchers at D. Boral Capital in a report issued on Wednesday,Benzinga reports. They presently have a $9.00 target price on the stock.

Kairos Pharma Stock Performance

NYSEAMERICAN:KAPA opened at $1.35 on Wednesday. Kairos Pharma has a one year low of $0.85 and a one year high of $4.00.

Kairos Pharma Company Profile

We are a clinical-stage biopharmaceutical company advancing therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer and glioblastoma.